Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China

Pacira Pharmaceuticals (NASDAQ:PCRX) has announced that it and Nuance Biotech have entered into an agreement with Nuance, a China-based speciality pharmaceutical company to advance the development and commercialization of EXPAREL in China.

As quoted in the press release:

EXPAREL is a non-opioid option for achieving long-lasting pain control after surgery via infiltration into the surgical site or administration as an interscalene brachial plexus nerve block.

“We are thrilled to expand the commercial opportunity for EXPAREL to China with a strong locally-based partner,” said Dave Stack, chairman and chief executive officer of Pacira. “Nuance’s highly talented leadership team has deep experience developing and commercializing innovative products in China using tailored sales and marketing strategies. We look forward to working with Nuance to make EXPAREL a success in China in support of our corporate mission to provide a non-opioid option to as many postsurgical patients as possible.”

“EXPAREL is an ideal fit for the Nuance portfolio given our focus on developing and commercializing innovative products for the Chinese market,” stated Mark G. Lotter, chief executive officer and co-founder of Nuance. “With proven expertise in developing and commercializing global brands, especially surgical products, I have every confidence that Nuance will maximize the commercial value of EXPAREL in China through a dedicated sales, marketing and market access effort, as well as an extensive network of key opinion leaders from influential academic centers.”

Click here to read the full press release.